INTENSITY THERAPEUTICS, INC.
INTSNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for INTS. That does not mean none is planned.
Get an email about INTS's next catalysts
Track INTENSITY THERAPEUTICS (INTS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
INTS Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.94 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
Eribulin
Sarcoma,Soft Tissue
INT230-6
Breast Cancer
anti-PD-1 antibody
Breast Cancer
anti-CTLA-4 antibody
Breast Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Eribulin | Phase 3 | Sarcoma,Soft Tissue | - | - |
INT230-6 | Phase 3 | Breast Cancer | - | - |
anti-PD-1 antibody | Phase 2 | Breast Cancer | - | - |
anti-CTLA-4 antibody | Phase 2 | Breast Cancer | - | - |
Sarcoma,Soft Tissue
1 drug in this indication
Breast Cancer
1 drug in this indication
triple-negative breast cancer
1 drug in this indication
Neoadjuvant triple-negative breast cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in INTENSITY THERAPEUTICS, INC.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in INTENSITY THERAPEUTICS, INC.'s (INTS) pipeline across Phase 3, Phase 2. Its lead program is Eribulin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is INTENSITY THERAPEUTICS, INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for INTENSITY THERAPEUTICS, INC. (INTS) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track INTS biotech catalysts?→
Add INTS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow INTENSITY THERAPEUTICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.